Phospholipid-Conjugated PEG-b-PCL Copolymers as Precursors of Micellar Vehicles for Amphotericin B

Elsa R Arias1, Vivian Angarita-Villamizar1, Yolima Baena2

  • 1Departamento de Química, Facultad de Ciencias, Universidad Nacional de Colombia-Sede Bogotá, Carrera 45 N° 26-85, Bogotá 11001, Colombia.

Polymers
|June 2, 2021
PubMed

Insights

This study modified polymer micelles (PMs) with DSPE to improve Amphotericin B (AmB) delivery. The DSPE-modified PMs enhanced AmB loading and antifungal activity while reducing toxicity.

Area of Science:

  • Polymer Chemistry
  • Nanotechnology
  • Pharmacology

Background:

  • Amphotericin B (AmB) is a broad-spectrum antifungal drug.
  • AmB exhibits significant nephrotoxicity, limiting its clinical use.
  • Polymer micelles (PMs) can reduce AmB toxicity but have limitations like low capacity and stability.

Purpose of the Study:

  • To investigate the effect of modifying poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) with 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine (DSPE) on PM performance for AmB delivery.

Main Methods:

  • PEG-b-PCL copolymers with varying PCL lengths were synthesized via ring-opening polymerization.
  • Copolymers were modified with DSPE through amidation.
  • DSPE-modified copolymers self-assembled into nanoparticles for AmB encapsulation.

Main Results:

  • DSPE modification resulted in nanoparticles <100 nm with lower critical micelle concentration.
  • AmB loading capacity increased due to intermolecular interactions (e.g., hydrogen bonds), reducing drug aggregation.
  • In vitro studies showed reduced AmB toxicity to red blood cells and enhanced antifungal activity against clinical yeasts.

Conclusions:

  • DSPE modification of PEG-b-PCL significantly improves PMs for Amphotericin B delivery.
  • This approach enhances AmB loading and efficacy while mitigating its toxicity.
  • DSPE-modified PMs represent a promising strategy for safer and more effective antifungal therapy.